Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1-mutated AML.
MDS
acute myeloid leukemia
secondary AML
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
08 Aug 2024
08 Aug 2024
Historique:
revised:
17
07
2024
received:
10
04
2024
accepted:
20
07
2024
medline:
8
8
2024
pubmed:
8
8
2024
entrez:
8
8
2024
Statut:
aheadofprint
Résumé
Nucleophosmin-1 (NPM1)-mutated AML is a molecularly defined subtype typically associated with favorable treatment response and prognosis; however, its prognostic significance in AML evolving from an antecedent chronic myeloid malignancy is unknown. This study's primary objective was to determine the impact of mutated NPM1 on the prognosis of AML evolving from an antecedent chronic myeloid malignancy. We conducted a retrospective chart review including patients with NPM1-mutated de novo and sAML. sAML was defined as those with a preceding chronic-phase myeloid malignancy before diagnosis of AML. Of 575 NPM1-mutated patients eligible for inclusion in our study, 51 (8.9%) patients were considered to have sAML. The median time from diagnosis of NPM1-mutated chronic myeloid malignancy to sAML evolution was 3.6 months (0.5-79.3 months). No significant differences in leukemia-free (2-year LKFS 52.0% vs. 51.2%, p = .9922) or overall survival (2-year OS 56.3% vs. 49.4%, p = .4246) were observed between patients with NPM1-mutated de novo versus sAML. Our study suggests that evolution from a preceding myeloid malignancy is not a significant predictor of poor prognosis in the setting of an NPM1 mutation. Our study demonstrated a short time to progression to sAML in most patients, which further supports the consideration of NPM1 as an AML-defining mutation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd.
Références
Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer. 2006;6(7):493‐505.
Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017;31(4):798‐807.
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209‐2221.
Falini B, Brunetti L, Sportoletti P, Martelli MP. NPM1‐mutated acute myeloid leukemia: from bench to bedside. Blood. 2020;136(15):1707‐1721.
Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424‐447.
Forghieri F, Nasillo V, Paolini A, et al. NPM1‐mutated myeloid neoplasms with <20% blasts: a really distinct clinico‐pathologic entity? Int J Mol Sci. 2020;21(23):8975.
Falini B, Martelli MP, Bolli N, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109‐1120.
Patel SS, Ho C, Ptashkin RN, et al. Clinicopathologic and genetic characterization of nonacute NPM1‐mutated myeloid neoplasms. Blood Adv. 2019;3(9):1540‐1545.
Forghieri F, Paolini A, Morselli M, et al. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms. Leuk Lymphoma. 2015;56(11):3222‐3226.
Courville EL, Wu Y, Kourda J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol. 2013 Jun;26(6):751‐761.
Schnittger S, Bacher U, Haferlach C, et al. Characterization of NPM1‐mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Leukemia. 2011;25(4):615‐621.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377.
Lachowiez CA, Loghavi S, Kadia TM, et al. Outcomes of older patients with NPM1‐mutated AML: current treatments and the promise of venetoclax‐based regimens. Blood Adv. 2020;4(7):1311‐1320.
Thiede C, Koch S, Creutzig E, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood. 2006;107(10):4011‐4020.
Tallman MS, Wang ES, Altman JK, et al. Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17(6):721‐749.
Hernández‐Sánchez A, Villaverde‐Ramiro Á, Martínez Elicegui J, et al. S130: NPM1 mutated AML: impact of co‐mutational patterns—results of the European Harmony Alliance. HemaSphere. 2022;6:31‐32.
Martínez‐Cuadrón D, Megías‐Vericat JE, Serrano J, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6(4):1278‐1295.
Morton LM, Dores GM, Tucker MA, et al. Evolving risk of therapy‐related acute myeloid leukemia following cancer chemotherapy among adults in the United States, 1975‐2008. Blood. 2013;121(15):2996‐3004.
Lancet JE, Uy GL, Cortes JE, et al. CPX‐351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36(26):2684‐2692.
Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367‐1376.
Gardin C, Pautas C, Fournier E, et al. Added prognostic value of secondary AML‐like gene mutations in ELN intermediate‐risk older AML: ALFA‐1200 study results. Blood Adv. 2020;4(9):1942‐1949.
Higgins A, Shah MV. Genetic and genomic landscape of secondary and therapy‐related acute myeloid leukemia. Genes. 2020;11(7):749.
Falini B, Macijewski K, Weiss T, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of AML with mutated nucleophosmin (NPM1). Blood. 2010;115(18):3776‐3786.
Díaz‐Beyá M, Rozman M, Pratcorona M, et al. The prognostic value of multilineage dysplasia in de novo acute myeloid leukemia patients with intermediate‐risk cytogenetics is dependent on NPM1 mutational status. Blood. 2010;116:6147‐6148.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703‐1719.
Zhao D, Zarif M, Eladl E, et al. NPM1‐mutated AML‐MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary‐type mutations and confers inferior outcome compared to AML with mutated NPM1. Leuk Res. 2022;118:106869.
Weinberg OK, Cantu MD, Gagan J, Madanat YF, Arber DA, Hasserjian RP. Presence but not number of secondary type mutations influences outcome in de novo AML without MDS‐associated or recurring cytogenetic abnormalities. EJHaem. 2023;4(3):760‐764.
Chan O, Al Ali N, Tashkandi H, et al. Secondary AML mutations confer poor prognosis in patients with ELN favorable risk NPM1‐mutated AML. Blood. 2022;140(supplement 1):3419‐3421.
Chan O, Al Ali N, Tashkandi H, et al. Mutations highly specific for secondary AML are associated with poor outcomes in patients with NPM1‐mutated ELN favorable risk AML. Blood. 2021;138:686.
Bill M, Eckardt JN, Rausch C, et al. Secondary‐type mutations do not impact the favorable outcome of NPM1‐mutated acute myeloid leukemia patients—results from a large cohort of intensively treated patients. Blood. 2023;142(supplement 1):721.
Wright MF, Pozdnyakova O, Hasserjian RP, et al. Secondary‐type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1. Am J Hematol. 2022;97:E462‐E465.
Eckardt JN, Bill M, Rausch C, et al. Secondary‐type mutations do not impact outcome in NPM1‐mutated acute myeloid leukemia—implications for the European LeukemiaNet risk classification. Leukemia. 2023;37(11):2282‐2285.
Peng J, Zuo Z, Fu B, et al. Chronic myelomonocytic leukemia with nucleophosmin (NPM1) mutation. Eur J Haematol. 2016;96(1):65‐71.
Vallapureddy R, Lasho TL, Hoversten K, et al. Nucleophosmin 1 (NPM1) mutations in chronic myelomonocytic leukemia and their prognostic relevance. Am J Hematol. 2017;92:E614‐E618.
Hwang SM, Kim SM, Nam Y, et al. Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. Leuk Res. 2019;84:106190.